Atamyo Therapeutics

Focus: Atamyo Therapeutics is an early-stage French biotech founded in 2020 specializing in gene therapies for neuromuscular diseases. The company operates at pre-revenue stage with focus on neurology-targeted therapeutic development.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Atamyo Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Atamyo Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Natural History Study in Patients With LGMDR5/2c

Gamma-sarcoglycanopathy

N/A

Clinical Trials (1)

NCT06210672Natural History Study in Patients With LGMDR5/2c

N/A

Help build intelligence for Atamyo Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a specialized gene therapy company in high-unmet-need neuromuscular space
European biotech location (Evry, France) offers access to strong academic neurology networks and EU regulatory pathways
Focused pipeline in emerging modality (gene therapy) with potential for significant clinical and commercial upside

Watch Out For

Pre-revenue stage with no disclosed funding details creates uncertainty around runway and long-term stability
No active clinical trials reported and zero job openings suggest company is in early discovery/preclinical phase with minimal near-term hiring
Limited public pipeline visibility and publication record raise questions about scientific momentum and validation

Generated by Claude from Atamyo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ATA-100

LGMDR9

Phase 1

Clinical Trials (1)

NCT05224505ATA-100 (Formerly GNT0006) Gene Therapy Trial in Patients With LGMDR9

Phase 1

ATA-200

LGMD2C

Phase 1

Clinical Trials (1)

NCT05973630ATA-200 Gene Therapy Trial in Patients With LGMDR5

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2020

Portfolio: 3 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo